皇家华人

The UCL-Pall/Cytiva Centre of Excellence (CoE), a strategic industrial research initiative, valued at 拢2.7m, will now continue until 2029 under a new 7-year agreement. With additional support of 拢1.6m from the EPSRC Prosperity Partnership, the Centre will train eight Engineering Doctorate (EngD) students, as well as other aligned doctoral students, bringing the total number of doctoral students trained to 20. Furthermore, it will fund four Post-Doctoral Research Associates (PDRAs) to spearhead their own synergistic research agendas, promoting knowledge exchange and facilitating coordinated EngD research focused on Cytiva industrial priorities.

The specialist research centre was setup to foster innovation, facilitate knowledge transfer, and address critical bioprocessing industrial challenges. The CoE has already yielded significant outcomes for both partners, and the new CoE will continue in its vision in bringing together leading key experts from both organizations. The new activity in "Smart Biomanufacturing for Genomic Medicines," aims to address the challenges of manufacturing revolutionary genomic medicines. These therapies have the potential to revolutionise medical treatments by delivering genetic molecules to disease sites to control protein production in cells and tissues. The partnership will improve patient access to these transformative therapies and establish manufacturing innovation in a high-growth sector that will result in societal and economic impact.

Find out more

• UCL Biochemical Engineering Centres of Excellence